GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite serious adverse events in about one-third of patients, the positive results support moving forward to Phase 3 trials. Analyst Michael Schmidt set a $54 price target for GMAB, suggesting significant upside from the current $34.75 share price, supported by strong financials including a 32.3% operating profit margin. Rina-S remains investigational, with safety and effectiveness yet to be fully established.
GMAB's Rina-S ovarian cancer trial results come as Pluang's Health sector shows 61 of 100 US stocks rising today. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: ADPT at USD 29.71 rose 4.80% with 100% sell orders, CYTK at USD 62.59 fell 4.59%, and TXG at USD 97.74 rose 4.53% with 73% buy orders and a typical hold time of 93 days.
BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...
Raymond James increased its price target for SBA Communications to $271 from $264, signaling a 68.6% upside from the current share price of $160.74. The growth is driven by rising mobile data demand, network expansions by wireless carriers, and stead...
The VIRTUAL token from Virtuals Protocol rose 10.57% to $0.877 within 24 hours as of early October 5, 2024. Despite the significant price gain, no specific event or catalyst was identified to explain the move. The token's total value locked, which in...
In Q3 2026, Lucid produced 2,954 vehicles but delivered 3,806, exceeding production by reducing existing inventory as part of a $1.4 billion cash flow improvement plan. The company aligned production with near-term demand, cutting a second shift at i...
Olin Corporation announced it will release its third quarter 2026 financial results on October 29, followed by a management review and Q&A session on October 30. The event will include a live webcast accessible via the company website and a telephoni...
